<DOC>
	<DOC>NCT01723670</DOC>
	<brief_summary>To evaluate the effects of multiple dose regimens of CHF 5074 administered once per day up to 2 years on potential biomarkers of neurodegeneration in subjects with mild cognitive impairment.</brief_summary>
	<brief_title>Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Nerve Degeneration</mesh_term>
	<criteria>One or two ∆ê4 alleles of the apolipoprotein E (APOE) gene. Diagnosis of amnestic Mild Cognitive Impairment. MiniMental State Examination score higher than 24 at screening. Diagnosis of Alzheimer's disease. Any medical condition that could explain the subject's cognitive deficits. MRI scans having evidence of prespecified brain abnormalities. History of stroke. Vitamin B12 or folate deficiency. Skin cancers and any cancer that is being actively treated. Diagnosis of schizophrenia or recurrent mood disorder. Abnormal kidney function. Concomitant use of any study prohibitive medication.</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>